https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12377 Sat 24 Mar 2018 10:34:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19187 0.5); however, significant treatment effects (p < 0.05) on the number of acid reflux episodes were observed with lower values on pumosetrag 0.2mg (10.8 ± 1.1), 0.5mg (9.5 ± 1.1), and 0.8mg (9.9 ± 1.1) compared with placebo (13.3 ± 1.1). Significant treatment effects (p < 0.05) were also observed for the percentage of time pH was <4, with less time for pumosetrag at 0.5mg (10%) and 0.8mg (10%) compared with placebo (16%). Conclusions & Inferences: In GERD, the partial 5HT3 agonist pumosetrag significantly reduced the rate of acid reflux events but did not result in a significant change in LESP or symptomatic improvement over a 1-week treatment period.]]> Sat 24 Mar 2018 07:55:04 AEDT ]]>